Bullous pemphigoid is an autoantibody-mediated skin blistering disease. Previous studies
revealed that intravenous Ig is therapeutic in animal models of bullous pemphigoid by …

Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by
autoantibodies to COL17. Currently, systemic corticosteroids are used as first-line treatments …

Numerous mechanisms of action have been proposed for intravenous Ig (IVIG). In this study,
we used IgG passive transfer murine models of bullous pemphigoid (BP), pemphigus …

Bullous pemphigoid is a potentially life-threatening autoantibody-mediated dermatosis
characterized by blister formation. Experimental mouse models of bullous pemphigoid …

Bullous pemphigoid (BP) is a prototypical organ-specific autoimmune disease.
Autoantibodies unfold their blister-inducing potential by triggering an Fcγ-dependent …

Background: Conventional therapy of severe bullous pemphigoid (BP) relies on the use of
high-dose systemic corticosteroids with or without adjuvants, notably immunosuppressive …

Bullous pemphigoid (BP) was first described by Lever in 1953 as a subepidermal blistering
disease. Key immunohistological features of BP include dermo-epidermal junction (DEJ) …

Background Various antibody-mediated autoimmune disorders are treated with intravenous
immunoglobulin (IVIg). While the exact action of IVIg is unknown, it likely acts to rapidly and …

Bullous pemphigoid (BP) is an autoimmune disease characterized by subepidermal
blistering. Based on previous work, IgG autoantibodies directed against BP180 are thought …

Bullous pemphigoid (BP) is a subepidermal blistering disease characterized by IgE and IgG
class autoantibodies specific for 180-kDa BP Ag 2 (BP180), a protein involved in cell …